$AKER Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in MyMD Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in MyMD Pharmaceuticals, Inc.. Get notifications about new insider transactions in MyMD Pharmaceuticals, Inc. for free.
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 22 2021 | AKER | MyMD Pharmaceutica ... | EAGLE CRAIG | Director | Option Exercise | A | 2.59 | 482,375 | 1,249,978 | 482,375 | |
Apr 22 2021 | AKER | MyMD Pharmaceutica ... | EAGLE CRAIG | Director | Option Exercise | A | 2.59 | 482,375 | 1,249,978 | 482,375 | |
Apr 21 2021 | AKER | MyMD Pharmaceutica ... | Schreiber Christopher C | Director | Option Exercise | M | 0.00 | 131,750 | 0 | 0 | |
Apr 21 2021 | AKER | MyMD Pharmaceutica ... | Schreiber Christopher C | Director | Payment of Exercise | F | 4.94 | 46,113 | 227,798 | 88,238 | 134.4 K to 88.2 K (-34.32 %) |
Apr 21 2021 | AKER | MyMD Pharmaceutica ... | Schreiber Christopher C | Director | Buy | M | 0.00 | 131,750 | 0 | 134,351 | 2.6 K to 134.4 K (+5,065.36 %) |
Apr 21 2021 | AKER | MyMD Pharmaceutica ... | Kaplin Adam | Chief Scientific Of ... | Option Exercise | A | 2.59 | 154,360 | 399,993 | 154,360 | |
Apr 21 2021 | AKER | MyMD Pharmaceutica ... | Kaplin Adam | Chief Scientific Of ... | Option Exercise | A | 2.59 | 154,360 | 399,993 | 154,360 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Rivard Paul | EVP of Operations, ... | Option Exercise | A | 2.59 | 77,180 | 199,997 | 77,180 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Rivard Paul | EVP of Operations, ... | Option Exercise | A | 2.59 | 77,180 | 199,997 | 77,180 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Rivard Paul | EVP of Operations, ... | Option Exercise | A | 2.59 | 77,180 | 199,997 | 77,180 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Rivard Paul | EVP of Operations, ... | Option Exercise | A | 2.59 | 77,180 | 199,997 | 77,180 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | SCHROEDER ROBERT C | Director | Option Exercise | M | 0.00 | 43,930 | 0 | 0 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | SCHROEDER ROBERT C | Director | Payment of Exercise | F | 4.94 | 14,694 | 72,588 | 29,236 | 43.9 K to 29.2 K (-33.45 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | SCHROEDER ROBERT C | Director | Buy | M | 0.00 | 43,930 | 0 | 43,930 | 0 to 43.9 K |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Silverman Joshua | Director | Option Exercise | M | 0.00 | 109,500 | 0 | 0 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Silverman Joshua | Director | Payment of Exercise | F | 4.94 | 38,325 | 189,326 | 71,175 | 109.5 K to 71.2 K (-35.00 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Silverman Joshua | Director | Buy | M | 0.00 | 109,500 | 0 | 112,101 | 2.6 K to 112.1 K (+4,209.92 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | White Billy Joe | Director | Option Exercise | M | 0.00 | 109,500 | 0 | 0 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | White Billy Joe | Director | Payment of Exercise | F | 4.94 | 38,325 | 189,326 | 71,175 | 109.5 K to 71.2 K (-35.00 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | White Billy Joe | Director | Buy | M | 0.00 | 109,500 | 0 | 112,101 | 2.6 K to 112.1 K (+4,209.92 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | SCHROEDER ROBERT C | Director | Option Exercise | M | 0.00 | 43,930 | 0 | 0 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | SCHROEDER ROBERT C | Director | Payment of Exercise | F | 4.94 | 14,694 | 72,588 | 29,236 | 43.9 K to 29.2 K (-33.45 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | SCHROEDER ROBERT C | Director | Buy | M | 0.00 | 43,930 | 0 | 43,930 | 0 to 43.9 K |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Silverman Joshua | Director | Option Exercise | M | 0.00 | 109,500 | 0 | 0 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Silverman Joshua | Director | Payment of Exercise | F | 4.94 | 38,325 | 189,326 | 71,175 | 109.5 K to 71.2 K (-35.00 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | Silverman Joshua | Director | Buy | M | 0.00 | 109,500 | 0 | 112,101 | 2.6 K to 112.1 K (+4,209.92 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | White Billy Joe | Director | Option Exercise | M | 0.00 | 109,500 | 0 | 0 | |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | White Billy Joe | Director | Payment of Exercise | F | 4.94 | 38,325 | 189,326 | 71,175 | 109.5 K to 71.2 K (-35.00 %) |
Apr 20 2021 | AKER | MyMD Pharmaceutica ... | White Billy Joe | Director | Buy | M | 0.00 | 109,500 | 0 | 112,101 | 2.6 K to 112.1 K (+4,209.92 %) |
Sep 11 2020 | AKER | Akers Biosciences, ... | White Billy Joe | Director | Option Exercise | A | 0.00 | 219,000 | 0 | 219,000 | |
Sep 11 2020 | AKER | Akers Biosciences, ... | Silverman Joshua | Director | Option Exercise | A | 0.00 | 219,000 | 0 | 219,000 | |
Sep 11 2020 | AKER | Akers Biosciences, ... | SCHROEDER ROBERT C | Director | Option Exercise | A | 0.00 | 87,860 | 0 | 87,860 | |
Sep 11 2020 | AKER | Akers Biosciences, ... | Schreiber Christopher C | Exec. Chairman and ... | Option Exercise | A | 0.00 | 263,500 | 0 | 263,500 | |
Mar 03 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Sell | S | 2.81 | 638 | 1,793 | 240,305 | 240.9 K to 240.3 K (-0.26 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 3.02 | 8,000 | 24,160 | 269,243 | 261.2 K to 269.2 K (+3.06 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 3.08 | 2,700 | 8,316 | 261,243 | 258.5 K to 261.2 K (+1.04 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 3.07 | 7,500 | 23,025 | 258,043 | 250.5 K to 258 K (+2.99 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 3.03 | 3,000 | 9,090 | 251,043 | 248 K to 251 K (+1.21 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 3.07 | 5,000 | 15,350 | 248,043 | 243 K to 248 K (+2.06 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 3.02 | 6,000 | 18,120 | 243,043 | 237 K to 243 K (+2.53 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 2.98 | 20,600 | 61,388 | 237,043 | 216.4 K to 237 K (+9.52 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 3.05 | 6,019 | 18,358 | 216,443 | 210.4 K to 216.4 K (+2.86 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 3.10 | 26,406 | 81,859 | 210,424 | 184 K to 210.4 K (+14.35 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 2.97 | 30,000 | 89,100 | 184,018 | 154 K to 184 K (+19.48 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 2.99 | 50,000 | 149,500 | 154,018 | 104 K to 154 K (+48.07 %) |
Jan 07 2020 | AKER | Akers Biosciences, ... | Hudson Bay Capital Management ... | 10% Owner | Buy | P | 2.96 | 19,353 | 57,285 | 104,018 | 84.7 K to 104 K (+22.86 %) |
Jan 03 2020 | AKER | Akers Biosciences, ... | Schreiber Christopher C | Executive Chairman | Option Exercise | M | 0.00 | 5,201 | 0 | 0 | |
Jan 03 2020 | AKER | Akers Biosciences, ... | Schreiber Christopher C | Executive Chairman | Buy | M | 0.00 | 5,201 | 0 | 5,201 | 0 to 5.2 K |
Jan 03 2020 | AKER | Akers Biosciences, ... | White Billy Joe | Director | Option Exercise | M | 0.00 | 5,201 | 0 | 0 | |
Jan 03 2020 | AKER | Akers Biosciences, ... | White Billy Joe | Director | Buy | M | 0.00 | 5,201 | 0 | 5,201 | 0 to 5.2 K |
Jan 03 2020 | AKER | Akers Biosciences, ... | Silverman Joshua | Director | Option Exercise | M | 0.00 | 5,201 | 0 | 0 | |
Jan 03 2020 | AKER | Akers Biosciences, ... | Silverman Joshua | Director | Buy | M | 0.00 | 5,201 | 0 | 5,201 | 0 to 5.2 K |
Sep 04 2019 | AKER | Akers Biosciences, ... | Yeaton Howard | CEO, CFO | Grant | A | 0.43 | 3,750 | 1,613 | 41,250 | 37.5 K to 41.3 K (+10.00 %) |
Aug 01 2019 | AKER | Akers Biosciences, ... | Yeaton Howard | CEO, CFO | Grant | A | 0.42 | 3,750 | 1,575 | 37,500 | 33.8 K to 37.5 K (+11.11 %) |
Jun 28 2019 | AKER | Akers Biosciences, ... | Yeaton Howard | CEO, CFO | Grant | A | 0.45 | 3,750 | 1,695 | 33,750 | 30 K to 33.8 K (+12.50 %) |
May 30 2019 | AKER | Akers Biosciences, ... | Yeaton Howard | CEO, CFO | Grant | A | 0.65 | 7,500 | 4,875 | 30,000 | 22.5 K to 30 K (+33.33 %) |
Apr 02 2019 | AKER | Akers Biosciences, ... | Silverman Joshua | Director | Option Exercise | A | 0.00 | 124,827 | 0 | 124,827 | |
Apr 02 2019 | AKER | Akers Biosciences, ... | White Billy Joe | Director | Option Exercise | A | 0.00 | 124,827 | 0 | 124,827 | |
Apr 02 2019 | AKER | Akers Biosciences, ... | Schreiber Christopher C | Director | Option Exercise | A | 0.00 | 124,827 | 0 | 124,827 | |
Mar 29 2019 | AKER | Akers Biosciences, ... | Yeaton Howard | CEO, CFO | Grant | A | 0.97 | 15,000 | 14,550 | 22,500 | 7.5 K to 22.5 K (+200.00 %) |
Jan 02 2019 | AKER | Akers Biosciences, ... | Yeaton Howard | CEO, CFO | Grant | A | 1.27 | 7,500 | 9,525 | 7,500 | 0 to 7.5 K |
Oct 24 2017 | AKER | Akers Biosciences, ... | RAUCH GARY M | VP - Finance, Treas ... | Grant | A | 0.88 | 36,277 | 31,924 | 63,777 | 27.5 K to 63.8 K (+131.92 %) |
Oct 24 2017 | AKER | Akers Biosciences, ... | Gormally John J | Chief Executive Off ... | Gift | G | 0.88 | 150,000 | 132,000 | 180,000 | 30 K to 180 K (+500.00 %) |
Jun 14 2016 | AKER | Akers Biosciences ... | Gormally John J | Chief Executive Off ... | Gift | G | 1.99 | 27,500 | 54,725 | 30,000 | 2.5 K to 30 K (+1,100.00 %) |
May 24 2016 | AKER | Akers Biosciences ... | Gormally John J | Chief Executive Off ... | Buy | P | 2.24 | 200 | 448 | 2,500 | 2.3 K to 2.5 K (+8.70 %) |
May 24 2016 | AKER | Akers Biosciences ... | Gormally John J | Chief Executive Off ... | Buy | P | 2.25 | 1,131 | 2,545 | 2,300 | 1.2 K to 2.3 K (+96.75 %) |
May 24 2016 | AKER | Akers Biosciences ... | Gormally John J | Chief Executive Off ... | Buy | P | 2.23 | 100 | 223 | 1,169 | 1.1 K to 1.2 K (+9.35 %) |
May 24 2016 | AKER | Akers Biosciences ... | Gormally John J | Chief Executive Off ... | Buy | P | 2.20 | 1,000 | 2,200 | 1,069 | 69 to 1.1 K (+1,449.28 %) |
May 24 2016 | AKER | Akers Biosciences ... | Gormally John J | Chief Executive Off ... | Buy | P | 2.19 | 69 | 151 | 69 | 0 to 69 |
Jan 06 2016 | AKER | Akers Biosciences ... | AKERS RAYMOND FRANCIS JR | Executive Chairman, ... | Buy | P | 1.34 | 2,100 | 2,814 | 72,100 | 70 K to 72.1 K (+3.00 %) |
Jan 05 2016 | AKER | Akers Biosciences ... | Knox Thomas J | Director | Grant | A | 0.00 | 70,000 | 0 | 478,150 | 408.2 K to 478.2 K (+17.15 %) |
Dec 31 2015 | AKER | Akers Biosciences ... | KNOX BRANDON THOMAS | Director | Grant | A | 0.00 | 55,000 | 0 | 138,076 | 83.1 K to 138.1 K (+66.20 %) |
Dec 31 2015 | AKER | Akers Biosciences ... | RAUCH GARY M | VP - Finance, Treas ... | Grant | A | 0.00 | 22,500 | 0 | 27,500 | 5 K to 27.5 K (+450.00 %) |
Dec 31 2015 | AKER | Akers Biosciences ... | Andrews Robert E | Director | Grant | A | 0.00 | 48,125 | 0 | 48,125 | 0 to 48.1 K |
Dec 31 2015 | AKER | Akers Biosciences ... | Bokhari Raza | Director | Grant | A | 0.00 | 32,083 | 0 | 32,083 | 0 to 32.1 K |
Dec 14 2015 | AKER | Akers Biosciences ... | RAUCH GARY M | VP - Finance, Treas ... | Buy | P | 1.50 | 3,500 | 5,250 | 5,000 | 1.5 K to 5 K (+233.33 %) |
Jan 12 2015 | AKER | Akers Biosciences ... | MORAN GAVIN | Director | Grant | A | 0.00 | 35,000 | 0 | 35,000 | 0 to 35 K |
Jan 12 2015 | AKER | Akers Biosciences ... | AKERS RAYMOND FRANCIS JR | Executive Chairman, ... | Option Exercise | G | 5.50 | 40,000 | 220,000 | 40,000 | |
Jan 12 2015 | AKER | Akers Biosciences ... | AKERS RAYMOND FRANCIS JR | Executive Chairman, ... | Gift | G | 0.00 | 70,000 | 0 | 70,000 | 140 K to 70 K (-50.00 %) |
Jan 12 2015 | AKER | Akers Biosciences ... | AKERS RAYMOND FRANCIS JR | Executive Chairman, ... | Grant | A | 0.00 | 70,000 | 0 | 70,000 | 0 to 70 K |
Jan 12 2015 | AKER | Akers Biosciences ... | Knox Thomas J | Director | Grant | A | 0.00 | 50,000 | 0 | 466,666 | 416.7 K to 466.7 K (+12.00 %) |
Jan 12 2015 | AKER | Akers Biosciences ... | KNOX BRANDON THOMAS | Director | Grant | A | 0.00 | 35,000 | 0 | 83,076 | 48.1 K to 83.1 K (+72.80 %) |
Aug 25 2014 | AKER | Akers Biosciences ... | RAUCH GARY M | VP of Finance, Trea ... | Buy | P | 3.15 | 1,020 | 3,213 | 1,500 | 480 to 1.5 K (+212.50 %) |
Jun 12 2014 | AKER | Akers Biosciences ... | Knox Thomas J | Director | Option Exercise | A | 5.50 | 20,000 | 110,000 | 20,000 | |
Jun 12 2014 | AKER | Akers Biosciences ... | RAUCH GARY M | Controller, Treasur ... | Option Exercise | A | 5.50 | 15,000 | 82,500 | 15,000 | |
Jun 12 2014 | AKER | Akers Biosciences ... | MORAN GAVIN | Director | Option Exercise | A | 5.50 | 20,000 | 110,000 | 20,000 | |
Jun 12 2014 | AKER | Akers Biosciences ... | AKERS RAYMOND FRANCIS JR | Executive Chairman, ... | Option Exercise | A | 5.50 | 40,000 | 220,000 | 40,000 | |
Jun 12 2014 | AKER | Akers Biosciences ... | KNOX BRANDON THOMAS | Director | Option Exercise | A | 5.50 | 20,000 | 110,000 | 20,000 |
Page: 1